- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

H.R. 3037
U.S. House•In House Committee
Summary
H.R. 3037, the Access to Breast Cancer Diagnosis Act of 2025, was introduced in the House on Apr 28, 2025 by Rep. Debbie Dingell (D) with 59 co-sponsors. It was referred to Energy And Commerce, and last saw action on Apr 28, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Record
Text
H.R. 3037 has 59 co-sponsors.
hb3037/introduced-in-house.txt119 HR 3037 IH: Access to Breast Cancer Diagnosis Act of 2025U.S. House of Representatives2025-04-28text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.I119th CONGRESS 1st SessionH. R. 3037IN THE HOUSE OF REPRESENTATIVESApril 28, 2025Mrs. Dingell (for herself, Mr. Fitzpatrick , and Ms. Wasserman Schultz ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concernedA BILLTo amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations.1.Short titleThis Act may be cited as the Access to Breast Cancer Diagnosis Act of 2025 .2.Requiring diagnostic and supplemental breast examinations to be covered with no cost-sharing requirements(a)In generalSubpart II of part A of title XXVII of the Public Health Service Act ( 42 U.S.C. 300gg–11 et seq. ) is amended by adding at the end the following new section:2730.Diagnostic and supplemental breast examinations(a)In generalIn the case of a group health plan, or a health insurance issuer offering group or individual health insurance coverage, that provides benefits with respect to diagnostic and supplemental breast examinations furnished to an individual enrolled under such plan or such coverage, such plan or coverage shall not impose any cost-sharing requirements for these benefits.(b)ConstructionNothing in this section shall be construed—(1)to prohibit a group health plan or health insurance issuer from requiring timely prior authorization or imposing other appropriate utilization controls in approving coverage for any diagnostic and supplemental breast examination; or(2)to supersede a State law that provides greater protections with respect to the coverage of diagnostic and supplemental breast examinations than is provided under this section.(c)DefinitionsIn this section:(1)Cost-sharing requirementsThe term cost-sharing requirements means a deductible, coinsurance, copayment, and any maximum limitation on the application of such a deductible, coinsurance, copayment or similar out-of-pocket expense.(2)Diagnostic breast examinationThe term diagnostic breast examination means a medically necessary and appropriate (in accordance with National Comprehensive Cancer Network Guidelines) examination of the breast (including, but not limited to such an examination using diagnostic mammography, breast magnetic resonance imaging, or breast ultrasound) that is—(A)used to evaluate an abnormality seen or suspected from a screening examination for breast cancer; or(B)used to evaluate an abnormality detected by another means of examination.(3)Supplemental breast examinationsThe term supplemental breast examination means a medically necessary and appropriate (in accordance with National Comprehensive Cancer Network Guidelines) examination of the breast (including, but not limited to such an examination using breast magnetic resonance imaging or breast ultrasound) that is—(A)used to screen for breast cancer when there is no abnormality seen or suspected; and(B)furnished based on personal or family medical history or additional factors that may increase the individual’s risk of breast cancer..(b)Application to grandfathered health plansSection 1251(a)(4)(A) of the Patient Protection and Affordable Care Act ( 42 U.S.C. 18011(a)(4)(A) ) is amended—(1)by striking title and inserting title, or as added after the date of the enactment of this Act ; and(2)by adding at the end the following new clause:(v)Section 2730 (relating to coverage for diagnostic and supplemental breast examinations)..(c)Application to high deductible health plans with health savings account eligibilitySection 223(c)(2) of the Internal Revenue Code of 1986 is amended by adding at the end the following:(H)Safe harbor for absence of deductible for diagnostic and supplemental breast examinationsIn the case of plan years beginning on or after January 1, 2026, a plan shall not fail to be treated as a high deductible health plan by reason of failing to have a deductible for diagnostic and supplemental breast examinations..(d)Effective dateThe amendments made by this section shall apply with respect to plan years beginning on or after January 1, 2026.
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-04-28
- Passed House
- Passed Senate
- Conference
- To President
- Became Law
To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations.
Sponsors
Rep. Debbie Dingell (D) sponsors H.R. 3037, and 59 members have co-sponsored it, 2 of them from the day it was introduced.

Rep. · D–MI-6 · Sponsor
Introduced Apr 28, 2025

Rep. · R–PA-1 · Co-sponsor
Joined Apr 28, 2025 · Original

Rep. · D–FL-25 · Co-sponsor
Joined Apr 28, 2025 · Original

Rep. · D–TX-37 · Co-sponsor
Joined Apr 29, 2025

Rep. · D–WI-4 · Co-sponsor
Joined Jun 6, 2025

Rep. · D–DC-0 · Co-sponsor
Joined Jun 12, 2025

Rep. · D–NM-1 · Co-sponsor
Joined Jun 20, 2025

Rep. · D–MA-6 · Co-sponsor
Joined Jun 24, 2025

Rep. · D–CT-5 · Co-sponsor
Joined Jul 14, 2025

Rep. · D–NY-26 · Co-sponsor
Joined Jul 23, 2025
Committees
H.R. 3037 went before 2 committees: Ways and Means and Energy and Commerce.
Actions
H.R. 3037 has taken 2 actions since Apr 28, 2025.
| Chamber | Action | |||
|---|---|---|---|---|
Apr 28, 2025 | House | Introduced in House | ||
Apr 28, 2025 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Energy and Commerce Committee |
Votes
H.R. 3037 has not gone to a roll call.
Related bills
1 bill is related to H.R. 3037, as Identical bill.
Titles
H.R. 3037 goes by 3 titles, 1 of them short titles.
- Access to Breast Cancer Diagnosis Act of 2025 — Display Title
- Access to Breast Cancer Diagnosis Act of 2025 — Short Title(s) as Introduced
- To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations. — Official Title as Introduced
Lobbying
7 clients hired 7 firms and 37 registered lobbyists who named H.R. 3037 in 32 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Health Issues, Budget/Appropriations, Medicare/Medicaid, Taxation/Internal Revenue Code, Insurance, Copyright/Patent/Trademark, Trade (domestic/foreign), Medical/Disease Research/Clinical Labs.
Clients
Who paid to be heard, by how many filings named the bill.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| NOVARTIS | — | District of Columbia | 1 | 7 | — |
| SUSAN G. KOMEN | organization addressing breast cancer through research, community health, public policy | Texas | 1 | 5 | $200K |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | — | District of Columbia | 1 | 5 | — |
| GE HEALTHCARE TECHNOLOGIES INC. | Global medical technology, pharmaceutical diagnostics and digital solutions company. | Illinois | 1 | 5 | — |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | — | Texas | 1 | 5 | — |
| HADASSAH, THE WOMEN'S ZIONIST ORGANIZATION OF AMERICA, INC. | — | New York | 1 | 3 | — |
| NOVARTIS, INC. | Multinational biopharmaceutical company | District of Columbia | 1 | 2 | $100K |
Firms
Registrants who filed on the bill, by filings.
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 37.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| COURTNEY LEE-ASHLEY | 1 | 1 | 7 |
| COURTNEY PIRON | 1 | 1 | 7 |
| JOSEPH MCGOWAN | 1 | 1 | 7 |
| SARAH DURR | 1 | 1 | 7 |
| TAYLOR BOOTH | 1 | 1 | 7 |
| THOMAS SUTER | 1 | 1 | 7 |
| LEO FARBER | 1 | 1 | 6 |
| ADAM FROMM | 1 | 1 | 5 |
| ALEXANDER SUTTON | 1 | 1 | 5 |
| BETSY TOWER | 1 | 1 | 5 |
| ELIZABETH DARNALL | 1 | 1 | 5 |
| ELIZABETH KARAN | 1 | 1 | 5 |
| JAMES WILLIAMS | 1 | 1 | 5 |
| JOHANNA GRAY | 1 | 1 | 5 |
| JULIE NICKSON | 1 | 1 | 5 |
| LESLIE BRADY | 1 | 1 | 5 |
| MARCELLA ORRIN | 1 | 1 | 5 |
| MARC GOTTSCHALK | 1 | 1 | 5 |
| MOLLY GUTHRIE | 1 | 1 | 5 |
| NISHITH PANDYA | 1 | 1 | 5 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| NOVARTIS | NOVARTIS | 2026 first_quarter | $3.9M | 1st Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2025 second_quarter | $2.6M | 2nd Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2025 fourth_quarter | $2.4M | 4th Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2026 first_quarter | $2.3M | 1st Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2025 third_quarter | $2.1M | 3rd Quarter - Report |
| NOVARTIS | NOVARTIS | 2025 third_quarter | $1.7M | 3rd Quarter - Amendme… |
| NOVARTIS | NOVARTIS | 2025 third_quarter | $1.6M | 3rd Quarter - Report |
| NOVARTIS | NOVARTIS | 2026 second_quarter | $1.4M | 2nd Quarter - Report |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | 2026 second_quarter | $1.2M | 2nd Quarter - Report |
| NOVARTIS | NOVARTIS | 2025 fourth_quarter | $1M | 4th Quarter - Report |
| NOVARTIS | NOVARTIS | 2025 second_quarter | $920K | 2nd Quarter - Amendme… |
| NOVARTIS | NOVARTIS | 2025 second_quarter | $880K | 2nd Quarter - Report |
| GE HEALTHCARE TECHNOLOGIES INC. | GE HEALTHCARE TECHNOLOGIES INC. | 2026 first_quarter | $700K | 1st Quarter - Report |
| GE HEALTHCARE TECHNOLOGIES INC. | GE HEALTHCARE TECHNOLOGIES INC. | 2025 fourth_quarter | $380K | 4th Quarter - Report |
| GE HEALTHCARE TECHNOLOGIES INC. | GE HEALTHCARE TECHNOLOGIES INC. | 2025 third_quarter | $370K | 3rd Quarter - Report |
| GE HEALTHCARE TECHNOLOGIES INC. | GE HEALTHCARE TECHNOLOGIES INC. | 2026 second_quarter | $350K | 2nd Quarter - Report |
| GE HEALTHCARE TECHNOLOGIES INC. | GE HEALTHCARE TECHNOLOGIES INC. | 2025 second_quarter | $350K | 2nd Quarter - Report |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 2025 second_quarter | $240K | 2nd Quarter - Report |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 2026 second_quarter | $130K | 2nd Quarter - Report |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 2026 first_quarter | $80K | 1st Quarter - Report |
Classification
The Congressional Research Service files H.R. 3037 under Health, one of its 31 policy areas.
CRS Subjects
CRS assigns every bill one policy area from its 31; H.R. 3037’s is Health.
hr3037/policy-areas.txtConstitutional authority
The clause the sponsor cites as Congress’s power to enact H.R. 3037, as entered in the Congressional Record.
[Congressional Record Volume 171, Number 70 (Monday, April 28, 2025)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mrs. DINGELL:H.R. 3037.Congress has the power to enact this legislation pursuantto the following:The Constitutional authority of Congress to enact thislegislation is provided by Article 1, Section 8 of the UnitedStates Constitution.[Page H1684]
Source: congress.gov · legiscan.com
